-
Base editing of the mutated TERT promoter inhibits liver tumor growth. Hepatology (IF 13.5) Pub Date : 2023-11-28 Gaoxiang Zhao,Qingxia Ma,Huang Yang,Hongfei Jiang,Qianqian Xu,Shudi Luo,Zhaoyuan Meng,Juanjuan Liu,Lei Zhu,Qian Lin,Min Li,Jing Fang,Leina Ma,Wensheng Qiu,Zhengwei Mao,Zhimin Lu
BACKGROUND AND AIMS Base editing has shown great potential for treating human diseases with mutated genes. However, its potential for treating hepatocarcinoma (HCC) has not yet explored. APPROACH AND RESULTS We employed adenine base editors (ABEs) to correct a TERT promoter mutation, which frequently occurs in various human cancers, including HCC. The mutated TERT promoter -124 C>T is corrected to
-
Looking for the best algorithm in diabetes population for advanced fibrosis detection: The best is the enemy of the good. Hepatology (IF 13.5) Pub Date : 2023-11-28 Manuel Romero-Gómez,Carmen Lara
-
Letter to the Editor: Alcohol-induced extracellular ASC specks perpetuate liver inflammation and damage in alcohol-associated hepatitis even after alcohol cessation. Hepatology (IF 13.5) Pub Date : 2023-11-28 Jiayan Shen,Kaiyue Zhang,Mengyang Liu,Tao Wang
-
PUS1 promotes hepatocellular carcinoma via mRNA pseudouridylation to enhance the translation of oncogenic mRNAs. Hepatology (IF 13.5) Pub Date : 2023-11-28 Yan-Xia Hu,Li-Ting Diao,Ya-Rui Hou,Guo Lv,Shuang Tao,Wan-Yi Xu,Shu-Juan Xie,Ya-Han Ren,Zhen-Dong Xiao
BACKGROUND AIMS Pseudouridine is a prevalent RNA modification and is highly present in the serum and urine of patients with hepatocellular carcinoma (HCC). However, the role of pseudouridylation and its modifiers in HCC remains unknown. We investigated the function and underlying mechanism of pseudouridine synthase 1 (PUS1) in HCC. APPROACH RESULTS By analyzing the TCGA data set, PUS1 was found significantly
-
Incorporation of genetic testing into the diagnostic algorithms of PALF: The time is now. Hepatology (IF 13.5) Pub Date : 2023-11-27 James E Squires,Simon P Horslen
-
Nuclear acly protects liver from ischemia-reperfusion injury. Hepatology (IF 13.5) Pub Date : 2023-11-20 Wenbin Gao,Liping Zhang,Ziru Li,Tong Wu,Chunhui Lang,Michael W Mulholland,Weizhen Zhang
BACKGROUND AIMS Hepatic ischemia-reperfusion (IR) injury is the most common complication that occurs in liver surgery and hemorrhagic shock. ATP citrate lyase (Acly) plays a pivotal role in chromatin modification via generating acetyl-CoA for histone acetylation to influence biological processes. We aim to examine the roles of Acly, which is highly expressed in hepatocytes, in liver IR injury. APPROACH
-
Letter To The Editor: A multi-society delphi consensus statement on new fatty liver disease nomenclature. Hepatology (IF 13.5) Pub Date : 2023-11-20 Jay H Hoofnagle,Edward Doo
-
The telomere Tango: Liver disease in the Genomic spotlight. Hepatology (IF 13.5) Pub Date : 2023-11-20 Kathryn A Schmidt,Douglas A Simonetto
-
Diagnostic accuracy of AGILE3+ score for advanced fibrosis in patients with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Hepatology (IF 13.5) Pub Date : 2023-11-17 Andrea Dalbeni,Rosa Lombardi,Matteus Henrique,Mirko Zoncapè,Grazia Pennisi,Salvatore Petta,Ryosuke Tateishi,Caglayan Keklikkiran,Antonio Colecchia,David Sacerdoti,Alessandro Mantovani,Federico Ravaioli
BACKGROUND AND AIMS A simple non-invasive score, the Agile3+ score, combining liver stiffness measurement (LSM), aspartate aminotransferase/alanine aminotransferase ratio, platelet count, diabetes status, sex, and age, has been proposed for identification of advanced fibrosis in patients with suspected non-alcoholic fatty liver disease (NAFLD). We performed a systematic review and meta-analysis of
-
Genetic landscape of pediatric acute liver failure of indeterminate origin. Hepatology (IF 13.5) Pub Date : 2023-11-17 Dominic Lenz,Lea D Schlieben,Masaru Shimura,Alyssa Bianzano,Dmitrii Smirnov,Robert Kopajtich,Riccardo Berutti,Rüdiger Adam,Denise Aldrian,Ivo Baric,Ulrich Baumann,Neslihan Eksi Bozbulut,Melanie Brugger,Theresa Brunet,Philip Bufler,Birutė Burnytė,Pier Luigi Calvo,Ellen Crushell,Buket Dalgıç,Anibh M Das,Antal Dezsőfi,Felix Distelmaier,Alexander Fichtner,Peter Freisinger,Sven F Garbade,Harald Gaspar,Louise
BACKGROUND AIMS Pediatric acute liver failure (PALF) is a life-threatening condition. In Europe, main causes are viral infections (12-16%) and inherited metabolic diseases (14-28%). Yet, in up to 50% of cases the underlying etiology remains elusive, challenging clinical management, including liver transplantation. We systematically studied indeterminate PALF cases referred for genetic evaluation by
-
A multicellular liver organoid model for investigating hepatitis C virus infection and non-alcoholic fatty liver disease progression. Hepatology (IF 13.5) Pub Date : 2023-11-17 Jaeseo Lee,Dayeon Gil,Hyeyeon Park,Youngsun Lee,Seon Ju Mun,Yongbo Shin,Eunji Jo,Marc P Windisch,Jung-Hyun Kim,Myung Jin Son
BACKGROUND AND AIMS HCV infection can be successfully managed with antiviral therapies; however, progression to chronic liver disease states, including NAFLD, is common. There is currently no reliable in vitro model for investigating host-viral interactions underlying the link between HCV and NAFLD; although liver organoids (LOs) show promise, they currently lack non-parenchymal cells, which are key
-
Prevalence and characteristics of Hepatitis delta virus infection in patients with hepatitis b in the united states: An analysis of the All-Payer Claims Database. Hepatology (IF 13.5) Pub Date : 2023-11-17 Robert G Gish,Ira M Jacobson,Joseph K Lim,Chris Waters-Banker,Ankita Kaushik,Chong Kim,Anissa Cyhaniuk,Robert J Wong
BACKGROUND AND AIMS Hepatitis delta virus (HDV) leads to the most severe form of viral hepatitis; however, the prevalence of HDV is not well understood. Using real-world data from the All-Payer Claims Database (APCD), this study estimates the prevalence of HBV/HDV infection among the chronic hepatitis B (HBV) population and describes patient/clinical characteristics for adults with HBV/HDV infection
-
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. Hepatology (IF 13.5) Pub Date : 2023-11-17 Madhumita Premkumar,Kamal Kajal,K Rajender Reddy,Manhal Izzy,Anand V Kulkarni,Ajay Kumar Duseja,K Bhupendra Sihag,Smita Divyaveer,Ankur Gupta,Sunil Taneja,Arka De,Nipun Verma,Sahaj Rathi,Harish Bhujade,Sreedhara B Chaluvashetty,Akash Roy,Vishesh Kumar,Vuppada Siddhartha,Virendra Singh,Ajay Bahl
BACKGROUND AIMS Treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI), with terlipressin and albumin, provides survival benefit, but may be associated with cardiopulmonary complications. We analysed the predictors of terlipressin response and mortality using point-of-care echocardiography (POC-Echo), cardiac and renal biomarkers. APPROACH Between December 2021 and January 2023, patients with
-
LRH-1 agonist DLPC through STAT6 promotes macrophage polarization and prevents parenteral nutrition associated cholestasis in mice. Hepatology (IF 13.5) Pub Date : 2023-11-17 Swati Ghosh,Michael W Devereaux,Cuining Liu,Ronald J Sokol
BACKGROUND AIMS Parenteral nutrition associated cholestasis (PNAC) is important complication in patients with intestinal failure with reduced LRH-1 expression. Here, we hypothesized that LRH-1 activation by its agonist, dilauroylphosphatidylcholine (DLPC), would trigger STAT6 signaling and hepatic macrophage polarization that would mediate hepatic protection in PNAC. APPROACH RESULTS PNAC mouse model
-
Erratum: Activation of pregnane X receptor sensitizes mice to hemorrhagic shock induced liver injury journal. Hepatology (IF 13.5) Pub Date : 2023-11-17
-
Erratum: Inhibition of mPGES-2 ameliorates non-alcoholic steatohepatitis by activating NR1D1 via heme. Hepatology (IF 13.5) Pub Date : 2023-11-17
-
Erratum: Diabetes and cirrhosis: Current concepts on diagnosis and management. Hepatology (IF 13.5) Pub Date : 2023-11-17
-
Benefit and harm of waiting time in liver transplantation for HCC. Hepatology (IF 13.5) Pub Date : 2023-11-16 Pam Elisabeth van der Meeren,Roeland Frederik de Wilde,Dave Sprengers,Jan Nicolaas Maria IJzermans
Liver transplantation is the most successful treatment for limited-stage HCC. The waiting time for liver transplantation (LT) can be a critical factor affecting the oncological prognosis and outcome of patients with HCC. Efficient strategies to optimize waiting time are essential to maximize the benefits of LT and to reduce the harm of delay in transplantation. The ever-increasing demand for donor
-
Letter to the Editor: Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry. Hepatology (IF 13.5) Pub Date : 2023-11-16 Shubei He,Ying Peng,Qinglin Wei
-
Single-cell dissection of the multicellular ecosystem and molecular features underlying microvascular invasion in hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-11-16 Li Ke,Zhang Rui,Wen Fukai,Zhao Yunzheng,Meng Fanshuai,Li Qingyu,Hao Aimin,Yang Bailu,Zhaoyang Lu,Cui Yifeng,Zhou Meng
BACKGROUND AND AIMS Microvascular invasion (MVI) is a crucial pathological hallmark of hepatocellular carcinoma (HCC), intricately associated with poor outcomes, early recurrence and intrahepatic metastasis following surgical resection and transplantation. However, the intricate tumor microenvironment (TME) and transcriptional programs underlying MVI in HCC remain poorly understood. APPROACH AND RESULTS
-
Hepatocytes of mice and men: Different regenerative signals? Hepatology (IF 13.5) Pub Date : 2023-11-16 George K Michalopoulos
-
Introducing the Editorial Fellow and the Fellows' Corner. Hepatology (IF 13.5) Pub Date : 2023-11-16 Harmeet Malhi,Gregory J Gores
-
Alcohol induced epigenetic changes prevent fibrosis resolution after alcohol cessation in mice. Hepatology (IF 13.5) Pub Date : 2023-11-09 Michael Schonfeld,Maura O'Neil,Steven A Weinman,Irina Tikhanovich
BACKGROUND AND AIMS Alcohol-associated liver disease (ALD) is a major cause of alcohol related mortality. Recently we identified hepatic demethylases KDM5B and KDM5C as important epigenetic regulators of alcohol response in the liver. In this study we aimed to investigate the role of KDM5-demethylases in ALD resolution. APPROACH AND RESULTS We showed that alcohol induced liver steatosis rapidly resolved
-
A Public health perspective on mitigating the global burden of chronic liver disease. Hepatology (IF 13.5) Pub Date : 2023-11-09 Maya Balakrishnan,Jürgen Rehm
Chronic liver disease (CLD) is a significant global health problem. Epidemiological trends do not show improvement in CLD incidence but rather a shift in etiologies, with steatotic liver disease (SLD) from metabolic dysfunction and alcohol becoming increasingly important causes. Consequently, there is a pressing need to develop a comprehensive public health approach for SLD. To that end, we propose
-
MicroRNA-206-3p suppresses hepatic lipogenesis and cholesterol synthesis while driving cholesterol efflux. Hepatology (IF 13.5) Pub Date : 2023-11-09 Ningning Liu,Jing Tian,Clifford J Steer,Qinghua Han,Guisheng Song
BACKGROUND AND AIMS Hepatosteatosis, hypertriglyceridemia, and hypertriglyceridemia are interconnected metabolic disorders. This study is designed to characterize how microRNA-206-3p (miR-206) simultaneously prevents de novo lipogenesis (DNL), cholesterol synthesis, and VLDL production in hepatocytes while promoting cholesterol efflux in macrophages. APPROACH AND RESULTS MiR-206 levels were reduced
-
AASLD Practice guidance on Acute-on-chronic liver failure and the management of critically Ill patients with cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-11-09 Constantine J Karvellas,Jasmohan S Bajaj,Patrick S Kamath,Lena Napolitano,Jacqueline G O'Leary,Elsa Solà,Ram Subramanian,Florence Wong,Sumeet K Asrani
-
Reply: Comparing quantitative MRI technologies in steatotic liver disease. Hepatology (IF 13.5) Pub Date : 2023-11-08 Jiahui Li,Alina M Allen,Meng Yin
-
Letter to Editor: Comparing quantitative MRI technologies in steatotic liver disease. Hepatology (IF 13.5) Pub Date : 2023-11-08 Naim Alkhouri,Mukesh Harisinghani
-
Letter to the Editor: How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma? Hepatology (IF 13.5) Pub Date : 2023-11-07 Zhi-Peng Liu,Xing-Hao Sun,Chao Yu,Xian-Yu Yin,Zhi-Yu Chen
-
Navigating the 'Specific Etiology' steatohepatitis category: Evaluation & management of non-alcohol/non-metabolic dysfunction-associated steatohepatitis. Hepatology (IF 13.5) Pub Date : 2023-11-07 Mohammad Qasim Khan,Sara Hassan,Blanca C Lizaola-Mayo,Mamatha Bhat,Kymberly D Watt
-
Rate and durability of clearance of hepatitis B surface antigen in Alaska Native persons with long-term hepatitis B virus infection: 1982-2019. Hepatology (IF 13.5) Pub Date : 2023-11-07 Dana Bruden,Brian J McMahon,Mary Snowball,Lisa Towshend-Bulson,Chriss Homan,Janet M Johnston,Brenna C Simons,Michael G Bruce,Laurie Cooley,Philip R Spradling,Aaron M Harris
BACKROUND AIMS A functional cure and therapeutic endpoint of chronic hepatitis B virus (HBV) infection is defined as clearance of hepatitis B surface antigen (HBsAg) from serum. Little is known about the long-term durability of HBsAg loss in the Alaskan Native population. APPROACH RESULTS We performed a retrospective cohort study of Alaskan Native patients with chronic HBV-monoinfection from January
-
Alternatives to animal testing to assess NASH drugs and hepatotoxicity. Hepatology (IF 13.5) Pub Date : 2023-11-06 David A Brenner
The Food and Drug Administration (FDA) Modernization Act 2.0 "allows for alternatives to animal testing for purposes of drug and biological product applications." This provides an opportunity to develop and improve alternatives to animal studies to assess drugs in the liver. Two dimensional cultures of liver cells fail to maintain their differentiated state and fail to reproduce liver disease phenotypes
-
Liver disease in germline mutations of telomere-related genes: Prevalence, clinical, radiological, pathological features, outcome, and risk factors. Hepatology (IF 13.5) Pub Date : 2023-11-06 Sabrina Sidali,Raphaël Borie,Flore Sicre de Fontbrune,Kinan El Husseini,Pierre-Emmanuel Rautou,Elodie Lainey,Odile Goria,Bruno Crestani,Jacques Cadrane,Vincent Cottin,Vincent Bune,Jérôme Dumortier,Emmanuel Jacquemin,Noémi Reboux,Sandrine Hirschi,Arnaud Bourdin,Magdalena Meszaros,Sebastien Dharancy,Sophie Hilaire,Vincent Mallet,Martine Reynaud-Gaubert,Louis Terriou,Frédéric Gottrand,Wadih Abou Chahla
BACKGROUND AND AIM Germline mutations of telomere-related genes (TRG) induce multiorgan dysfunction, and liver-specific manifestations have not been clearly outlined. We aimed to describe TRG mutations-associated liver diseases. APPROACH AND RESULTS Retrospective multicentre analysis of liver disease (transaminases>30 IU/L and/or abnormal liver imaging) in patients with TRG mutations. Main measurements
-
The chemokine CXCL14 is a novel early prognostic biomarker for poor outcome in acetaminophen-induced acute liver failure. Hepatology (IF 13.5) Pub Date : 2023-11-01 David S Umbaugh,Nga T Nguyen,Steven C Curry,Jody A Rule,William M Lee,Anup Ramachandran,Hartmut Jaeschke,
BACKGROUND AND AIMS Patients with acetaminophen-induced acute liver failure (APAP-ALF) are more likely to die while on the liver transplant waiting list than those with other causes of ALF. Therefore, there is an urgent need for prognostic biomarkers that can predict the need for liver transplantation early after an APAP overdose. APPROACH AND RESULTS We evaluated the prognostic potential of plasma
-
Reply: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence severity, and long-term outlook for SLD and subclassifications. Hepatology (IF 13.5) Pub Date : 2023-10-31 Brian P Lee,Jennifer L Dodge,Norah A Terrault
-
Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-10-31 Wen-Juei Jeng,Rong-Nan Chien,Yun-Fan Liaw
-
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-10-31 Rui Deng,Ziyan Wang,Yuxin Liu,Jian Sun
-
Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma". Hepatology (IF 13.5) Pub Date : 2023-10-31 Francesca Ratti,Rebecca Marino,Bas Groot Koerkamp,Luca Aldrighetti
-
Letter to the Editor: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence, severity, and long-term outlook for SLD and subclassifications. Hepatology (IF 13.5) Pub Date : 2023-10-31 Haoxuan Zou,Yan Xie
-
Cystic fibrosis screening, evaluation and management of hepatobiliary disease consensus recommendations. Hepatology (IF 13.5) Pub Date : 2023-10-26 Zachary M Sellers,David N Assis,Shruti M Paranjape,Meghana Sathe,Frank Bodewes,Melissa Bowen,Marco Cipolli,Dominique Debray,Nicole Green,Kara S Hughan,William R Hunt,Julio Leey,Simon C Ling,Giuseppe Morelli,Daniel Peckham,Rebeca S Pettit,Alexander Philbrick,Janis Stoll,Kay Vavrina,Stacy Allen,Tara Goodwin,Sarah E Hempstead,Michael R Narkewicz
Background and Aims Cystic fibrosis (CF) may cause a spectrum of hepatobiliary complications, including portal hypertension, multilobular cirrhosis, and liver failure. Current guidelines on the detection and monitoring of hepatobiliary complications in CF were published in 1999. The CF Foundation assembled a committee to evaluate research advances and formulate revised guidelines for CF-associated
-
Mendelian Randomization in hepatology: A review of principles, opportunities, and challenges. Hepatology (IF 13.5) Pub Date : 2023-10-24 Yilin Song,Ting Ye,Lewis R Roberts,Nicholas B Larson,Stacey J Winham
Mendelian Randomization has become a popular tool to assess causal relationships using existing observational data. While randomized controlled trials are considered the gold standard for establishing causality between exposures and outcomes, it is not always feasible to conduct a trial. Mendelian Randomization is a causal inference method that uses observational data to infer causal relationships
-
FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Hepatology (IF 13.5) Pub Date : 2023-10-24 Changle Ke,Changchen Xiao,Jiamin Li,Xianpeng Wu,Yu Zhang,Yongjian Chen,Shuyuan Sheng,Zaiyang Fu,Lingjun Wang,Cheng Ni,Jing Zhao,Yanna Shi,Yan Wu,Zhiwei Zhong,Jinliang Nan,Wei Zhu,Jinghai Chen,Rongrong Wu,Xinyang Hu
BACKGROUND AND AIMS Nonalcoholic fatty liver disease (NAFLD), comprises a spectrum of liver disorders with the initial abnormal accumulation of lipids in hepatocytes called nonalcoholic fatty liver (NAFL), progressing to the more serious non-alcoholic steatohepatitis (NASH) in a subset of individuals. Our previous study revealed that global flavin-containing monooxygenase 2 (FMO2) knockout causes higher
-
Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets. Hepatology (IF 13.5) Pub Date : 2023-10-23 Tao Yang,Xiaoye Qu,Xiao Wang,Dongwei Xu,Mingwei Sheng,Yuanbang Lin,Michael Ke,Ci Song,Qiang Xia,Longfeng Jiang,Jun Li,Douglas G Farmer,Bibo Ke
BACKGROUND AIMS The hallmark of nonalcoholic fatty liver disease (NAFLD) or hepatic steatosis is characterized by lipid droplet (LD) accumulation in hepatocytes. Autophagy may have profound effects on lipid metabolism and innate immune response. However, how innate immune activation may regulate the autophagic degradation of intracellular LDs remains elusive. APPROACH RESULTS A mouse model of a high-fat
-
Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win. Hepatology (IF 13.5) Pub Date : 2023-10-23 Ya-Fei Hu,Wen-Jie Ma,Yan-Wen Jin,Fu-Yu Li
-
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-10-23 David E Kaplan,Jaime Bosch,Cristina Ripoll,Maja Thiele,Brett E Fortune,Douglas A Simonetto,Guadalupe Garcia-Tsao
-
Wnt/β-catenin and NFκB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes. Hepatology (IF 13.5) Pub Date : 2023-10-23 Nuria Oliva-Vilarnau,Christian M Beusch,Pierre Sabatier,Eirini Sakaraki,Amelie Tjaden,Lukas Graetz,Florian A Büttner,Debra Dorotea,My Nguyen,Filip Bergqvist,Yvonne Sundström,Susanne Müller,Roman A Zubarev,Gunnar Schulte,Claudia Tredup,Roberto Gramignoli,Uwe J F Tietge,Volker M Lauschke
BACKGROUND AIMS The liver has a remarkable capacity to regenerate, which is sustained by the ability of hepatocytes to act as facultative stem cells that, while normally quiescent, re-enter the cell cycle after injury. Growth factor signaling is indispensable in rodents, whereas Wnt/β-catenin is not required for effective tissue repair. However, the molecular networks that control human liver regeneration
-
A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-10-23 Ching-Wen Chang,Yu-Syuan Chen,Chen-Hua Huang,Chao-Hsiung Lin,Wailap Victor Ng,Lichieh Julie Chu,Eric Trépo,Jessica Zucman-Rossi,Kevin Siao,Jacquelyn J Maher,Men Yee Chiew,Chih-Hung Chou,Hsien-Da Huang,Wan-Huai Teo,I-Shan Lee,Jeng-Fan Lo,Xin Wei Wang
BACKGROUND AIMS Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease worldwide but only a subset of NAFLD individuals may progress to nonalcoholic steatohepatitis (NASH). While NASH is an important etiology of hepatocellular carcinoma (HCC), the underlying mechanisms responsible for conversion of NAFLD to NASH, and then to HCC are poorly understood. We aimed to identify
-
Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis. Hepatology (IF 13.5) Pub Date : 2023-10-23 Robert G Gish,Robert J Wong,Gian Luca Di Tanna,Ankita Kaushik,Chong Kim,Nathaniel J Smith,Patrick T F Kennedy
BACKGROUND AIMS Studies have suggested that patients with chronic hepatitis B (CHB), either co-, or super infected, have more aggressive liver disease progression than those with the hepatitis delta virus (HDV). This systematic literature review and meta-analysis examined whether HDV RNA status is associated with increased risk of advanced liver disease events (ALDEs), in patients who are HBsAg and
-
Development of Fibro-PeN, a clinical prediction model for moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Hepatology (IF 13.5) Pub Date : 2023-10-23 Andrew Wang,Amanda L Blackford,Cynthia Behling,Laura A Wilson,Kimberly P Newton,Stavra A Xanthakos,Mark H Fishbein,Miriam B Vos,Marialena Mouzaki,Jean P Molleston,Ajay K Jain,Paula Hertel,Kathryn Harlow Adams,Jeffrey B Schwimmer,
BACKGROUND AND AIMS Liver fibrosis is common in children with nonalcoholic fatty liver disease (NAFLD) and an important determinant of outcomes. High performing non-invasive models to assess fibrosis in children are needed. The objectives of this study were to evaluate the performance of existing pediatric and adult fibrosis prediction models and to develop a clinical prediction rule for identifying
-
Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab. Hepatology (IF 13.5) Pub Date : 2023-10-23 Claudia Campani,Ariane Vallot,Haroun Ghannouchi,Manon Allaire,Manon Evain,Philippe Sultanik,Sabrina Sidali,Lorraine Blaise,Dominique Thabut,Pierre Nahon,Olivier Seror,Nathalie Ganne-Carrié,Jean-Charles Nault,Mathilde Wagner,Olivier Sutter
BACKGROUND AIMS We aim to assess the role of radiological response to atezolizumab-bevacizumab (AtezoBev) in patients with hepatocellular carcinoma (HCC) to predict overall survival (OS). APPROACH RESULTS We retrospectively included HCC patients treated by AtezoBev in two tertiary centers. A retrospective blinded analysis was performed by two radiologists to assess RECIST1.1 and mRECIST criteria at
-
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes. Hepatology (IF 13.5) Pub Date : 2023-10-20 Veeral Ajmera,Kaleb Tesfai,Erick Sandoval,Scarlett Lopez,Vanessa Cervantes,Egbert Madamba,Ricki Bettencourt,Pinelopi Manousou,Lisa Richards,Rohit Loomba
BACKGROUND AND AIMS Recently, the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) developed clinical pathways to evaluate populations at high-risk for nonalcoholic fatty liver disease (NAFLD). We assessed the diagnostic performance of the new guidance in a well-phenotyped cohort of patients with Type 2 diabetes mellitus (T2DM). APPROACH
-
Letter to the Editor: Contrasting effect of iron supplementation iron in protoporpyria. Hepatology (IF 13.5) Pub Date : 2023-10-20 Jasmin Barman-Aksözen,Anna-Elisabeth Minder,Detlef Schuppan,Ulrich Stölzel
-
Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding? Hepatology (IF 13.5) Pub Date : 2023-10-20 Edo J Dongelmans,Milan J Sonneveld,Harry L A Janssen
-
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease. Hepatology (IF 13.5) Pub Date : 2023-10-20 Luis Antonio Diaz,Gerald Scott Winder,Lorenzo Leggio,Jasmohan S Bajaj,Ramon Bataller,Juan Pablo Arab
Alcohol use disorder (AUD) remains a significant public health concern, affecting around 5% of adults worldwide. Novel pathways of damage have been described during the last years, providing insight into the mechanism of injury due to alcohol misuse beyond the direct effect of ethanol byproducts on the liver parenchyma and neurobehavioral mechanisms. Thus, the gut-liver-brain axis and immune system
-
Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding? Hepatology (IF 13.5) Pub Date : 2023-10-20 Yun-Fan Liaw,Wen-Juei Jeng,Rong-Nan Chien
-
The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023. Hepatology (IF 13.5) Pub Date : 2023-10-12
-
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophage to improve chemotherapy efficacy against liver tumor. Hepatology (IF 13.5) Pub Date : 2023-10-09 Dan Yang,Taikun Tian,Xiaojing Li,Baokai Zhang,Linlin Qi,Fan Zhang,Mingshun Han,Shuang Wang,Jun Xiao,Yingying Gou,Raorao Zhang,Qiaojie Liu,Sheng Su,Jiahui Liu,Xiaowu Huang,Qiang Gao,Lijian Hui,Huiru Tang,Hongyan Wang,Bin Wei
BACKGROUND AIMS Hepatocellular carcinoma (HCC) is closely associated with inflammation and immune modulation, and combined chemotherapy with other strategies is under extensive investigation to achieve better efficacy. HCC is accompanied by zinc deficiency. This study aims to understand how zinc could affect macrophage function and its application for HCC therapy. APPROACH RESULTS Zn2+ and the zinc
-
Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon. Hepatology (IF 13.5) Pub Date : 2023-10-09 Randa Elsheikh,Abdelrahman M Makram,Nguyen Tien Huy
-
Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-10-09 Stephanie Ma,Valerie Chew
-
Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon. Hepatology (IF 13.5) Pub Date : 2023-10-09 Barath Jagadisan,Anil Dhawan